![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Analysis of Resistance-Associated Mutations in Patients treated with narlaprevir and subsequently standard of care
|
|
|
Reported by Jules Levin
61st AASLD Nov 2 2010 Boston
Reesink HW2, Weegink CJ2, Treitel MA3, Hughes EA3, Rebers SP1, Bergmann J4 de Knegt RJ4, van Vliet A5, Janssen HLA4, Molenkamp R1, Schinkel J1 Academic Medical Center, 1Department of Medical Microbiology, Section of Clinical Virology and 2Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands; 3Merck Research Laboratories, Kenilworth, NJ; 4Erasmus MC University Hospital, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands; 5PRA International, Zuidlaren, The Netherlands.
![](../images/112110/112110-17/end-1.gif)
![](../images/112110/112110-17/obj-2.gif)
![](../images/112110/112110-17/desug-3.gif)
![](../images/112110/112110-17/clonla-4.gif)
![](../images/112110/112110-17/variant-5.gif)
![](../images/112110/112110-17/fig3-6.gif)
![](../images/112110/112110-17/wash-7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|